logo
Sign in

NURPF Stock Price, Chart, Stats & News

Neuren Pharmaceuticals Limited
Save

Neuren Pharmaceuticals Limited (NURPF) does not currently pay a dividend.

1.77B
Market cap
132.28x
Current P/E
39.06x
Forward P/E

NURPF chart

About

Health care
Sector
Biotechnology
Industry

Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome. The company is also progressing NNZ-2591, which has finished its initial human trials (Phase I) for a spectrum of rare neurodevelopmental disorders, including Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes.

Similar securities

Based on sector and market capitalization

Report issue